Morgan Health, CVS Health Ventures, and Humana, alongside other strategic payers and providers, invest in Thyme Care at a valuation of more than $2B

摩根健康（Morgan Health）、CVS健康风投（CVS Health Ventures）和Humana，以及其他战略支付方和提供方，以超过20亿美元的估值投资Thyme Care

The new capital accelerates Thyme Care's continued growth and establishes Thyme Companies, a newly formed parent entity building a broader portfolio of businesses to tackle distinct parts of the oncology journey

新资本加速了Thyme Care的持续增长，并成立了Thyme Companies，这是一家新成立的母公司，旨在构建更广泛的业务组合，以应对癌症治疗旅程中的不同环节。

NASHVILLE, Tenn.

田纳西州纳什维尔

,

，

Sept. 2, 2026

2026年9月2日

/PRNewswire/ --

/美通社/ --

Thyme Care

百里香护理

, the nationally recognized oncology company, today announced a new Series E financing round of over $125M.

这家全国知名的肿瘤学公司今天宣布完成新一轮超过1.25亿美元的E系列融资。

Morgan Health

摩根健康

led the round, with participation from strategic healthcare investors

领投本轮融资，并有战略医疗投资者参与

Humana

Humana

and

和

CVS Health Ventures

CVS Health 风险投资部门

, as well as institutional investors

以及机构投资者

AlleyCorp

AlleyCorp

,

，

HealthQuest Capital

健康探索资本

,

，

Foresite Capital

Foresite Capital

,

，

Concord Health Partners

康科德健康伙伴

,

，

Frist Cressey Ventures

弗里斯特·克雷西风险投资公司

,

，

Town Hall Ventures

市政厅风险投资公司

, and

，和

a16z Bio + Health

a16z 生物与健康

.

。

The financing brings together strategic investors from across the cancer care ecosystem, including the largest national payers, community oncology, health systems, and leaders in employer-sponsored health care, reflecting favorable investor outlook on Thyme Care's care model and its potential to take on the broader challenges in cancer care.

本轮融资汇聚了来自癌症护理生态系统的战略投资者，包括全国最大的支付方、社区肿瘤科、医疗系统以及雇主赞助医疗保健领域的领导者，这反映出投资者对Thyme Care护理模式的看好，以及对其应对癌症护理更广泛挑战的潜力的认可。

Today, Thyme Care services are available to more than 10.5 million people across all 50 states, and the company manages more than $7 billion in oncology spend. By aligning care around the patient, the model delivers 5 to 10 percent validated reductions in total cost of care, creating measurable value for patients, providers, and health plan partners.

如今，Thyme Care 的服务已覆盖美国全部 50 个州的超过 1,050 万人群，公司管理的肿瘤学支出超过 70 亿美元。通过以患者为中心协调照护，该模式实现了经验证的总照护成本 5% 至 10% 的降低，为患者、医疗服务提供者以及健康计划合作伙伴创造了可衡量的价值。

Supported by strong financial discipline, Thyme Care is profitable, generates meaningful positive free cash flow, and is positioned to accelerate its next phase of growth..

在严格的财务纪律支持下，Thyme Care 已实现盈利，产生可观的正向自由现金流，并蓄势加速推进下一阶段的成长。

'People living with cancer have traditionally been left to coordinate care themselves and pay more along the way. Thyme Care is changing that experience and making it possible to improve cancer care while lowering costs,' said Dan Mendelson, chief executive officer of Morgan Health. 'We're continuing to invest in Thyme Care because we're confident they can continue to deliver value to patients and payers – as they make the next wave of cancer care innovation easier to access and navigate.'.

“癌症患者传统上不得不自行协调护理，并在此过程中承担更高的费用。Thyme Care 正在改变这一现状，使得在降低费用的同时改善癌症护理成为可能，”Morgan Health 首席执行官丹·门德尔森表示。“我们继续投资 Thyme Care，因为我们相信他们能够持续为患者和支付方创造价值——因为他们让下一波癌症护理创新更易于获取和导航。”

Alongside the Series E, Thyme Care is establishing

在E轮融资的同时，Thyme Care正在建立

Thyme Companies

百里香公司

, a newly formed parent entity designed to build a portfolio of new, independent businesses in oncology that address persistent barriers to better cancer care. Grounded in data, enabled by technology, and built on trusted partnerships, Thyme Companies is positioned to take on oncology's biggest challenges.

，这是一家新成立的母公司，旨在构建一系列专注于肿瘤学的新型独立企业，以解决改善癌症护理过程中长期存在的障碍。Thyme Companies 以数据为基石，以技术为驱动，依托值得信赖的合作伙伴关系，致力于应对肿瘤学领域最重大的挑战。

Areas under active development include accelerating the adoption of lower-cost biosimilars and improving clinical trial accrual, where slow enrollment limits patient access to beneficial trials and slows drug development. The first of these businesses is expected to launch later this year..

正在积极开发的领域包括加速推广低成本生物类似药，以及改善临床试验的受试者招募工作，因为招募进度缓慢会限制患者参与有益试验的机会，并延缓药物研发进程。预计首个相关业务将于今年晚些时候启动。

To support this next phase of growth, Thyme Care co-founder

为支持这一下一阶段的增长，Thyme Care 联合创始人

Robin Shah

罗宾·沙阿

will serve as executive chairman of Thyme Companies leading the strategy and development of new businesses and working closely with his co-founder

将担任Thyme公司的执行董事长，领导新业务的战略和发展，并与他的联合创始人密切合作。

Bobby Green, M.D.

鲍比·格林，医学博士

to bring the connected, patient-first approach that built Thyme Care, to a broader set of healthcare challenges. Thyme Care continues under CEO

将构建 Thyme Care 的互联、以患者为先的方法，应用于更广泛的医疗健康挑战。Thyme Care 在首席执行官的领导下继续发展

Brad Diephuis, M.D.

布拉德·迪普豪斯，医学博士

, with Dr. Green as president and chief medical officer. Thyme Care remains the anchor of the Thyme Companies family of businesses; its name, partnerships, and member experience unchanged.

由格林博士担任总裁兼首席医疗官。Thyme Care 仍然是 Thyme Companies 企业集团的核心业务；其名称、合作伙伴关系及会员体验均保持不变。

'When we founded Thyme Care, our vision was never limited to one part of cancer care. We wanted to create a better oncology care system,' says Shah. 'Thyme Care showed it could be done, and as we've grown alongside patients, providers and health plans, we've gained a deep perspective on the challenges that get in the way of better care.

“在创立Thyme Care时，我们的愿景从未局限于癌症护理的某一个环节。我们希望打造一个更优质的肿瘤护理体系。”Shah表示。“Thyme Care证明了这一目标是可以实现的。随着我们与患者、医疗服务提供者以及健康保险计划共同成长，我们对阻碍优质护理的各种挑战形成了深刻的见解。”

Thyme Companies is the next step in this journey, enabling us to build new solutions fully informed by what we've learned, while continuing to invest in the core business that made it possible.'.

Thyme Companies 是这一征程的下一步，使我们能够基于所获经验全面构建新解决方案，同时继续投资于成就今日的核心业务。

About Thyme Companies

关于 Thyme Companies

Thyme Companies is the parent of the Thyme family of businesses, focused on building companies against the disconnection in how cancer care is delivered, accessed and paid for. Anchored by Thyme Care, the nationally recognized oncology care company, Thyme Companies develops independent businesses connected by one mission: to transform the experience of cancer for the people living through it.

Thyme Companies是Thyme系列企业的母公司，致力于解决癌症护理在提供、获取和支付方面的脱节问题。以全国知名的肿瘤护理公司Thyme Care为核心，Thyme Companies开发与运营多家独立企业，这些企业由一个共同使命紧密相连：为癌症患者改善其抗癌历程中的整体体验。

To learn more, visit .

欲了解更多信息，请访问。

thymecompanies.com

thymecompanies.com

.

。

About Thyme Care

关于 Thyme Care

Thyme Care aligns accountability across the cancer care journey, coordinating patients, providers, and health plans around a shared model of care that drives better outcomes and lower costs for everyone. Through dedicated care teams and technology, Thyme Care integrates directly into existing workflows to support patients longitudinally, close gaps between visits, and align clinical decisions with financial accountability.

Thyme Care 在整个癌症诊疗过程中统一各方责任，围绕一种共享的护理模式协调患者、医疗服务提供者和健康保险计划，从而为所有相关方带来更好的治疗结果和更低的成本。通过专属的护理团队和技术支持，Thyme Care 直接融入现有的工作流程，为患者提供长期持续的支持，填补就诊间隔期的照护空白，并使临床决策与财务责任保持一致。

To learn more, visit .

欲了解更多信息，请访问。

thymecare.com

thymecare.com

.

。

Inkhouse for Thyme Care

百里香护理墨屋

[email protected]

[email protected]

SOURCE Thyme Care

来源：Thyme Care

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示